The Company Maintains a Strong Balance Sheet Following Submission to the FDA of Its First New Drug Application for RHB-103 RedHill Plans to Submit a Second NDA, for RHB-102 , by the First or Second Quarter of 2014 and Continues to Advance the Planned Phase III and Phase II/III Studies With RHB-104 and RHB-105 , Respectively TEL-AVIV, Israel, May 2, ... (more)
More...
More...